White House Backtracks on Plan to Exert New Control Over N.I.H. Grants

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-23 • Permanent link

Fears have been heightened among investors as the White House has announced a last-minute reversal on plans to exert new control over National Institutes of Health (NIH) grants. The proposed commission, which was met with fierce opposition from Democrats and Republicans in Congress, would have given it the power to veto federal research awards. This sudden change has sent shockwaves through the market, with the Dow Jones Industrial Average plummeting by 2.5% in early trading. The NIH's budget, which accounts for approximately 15% of the federal budget, is a crucial component of the overall economic landscape.

As a result of this development, investors are breathing a sigh of relief, but experts warn that this is only a temporary reprieve. The NIH's grants play a vital role in driving innovation and advancing medical research, and any disruption to this process could have far-reaching consequences for the economy. Furthermore, the NIH's budget is already under pressure due to the ongoing pandemic, and any further changes could exacerbate existing concerns. The NIH's director, Francis Collins, has issued a statement assuring the public that the agency will continue to operate with minimal disruption.

The White House's decision to backpedal on this plan has been seen as a strategic move to appease lawmakers and avoid a potentially contentious battle. Since last quarter, there have been growing concerns about the NIH's budget, with some lawmakers calling for greater transparency and oversight. The NIH's budget has been the subject of intense scrutiny in recent years, with some critics arguing that it is too large and inefficient. The White House's reversal may be seen as a pragmatic response to these concerns.

As the dust settles on this latest development, investors will be keeping a close eye on the NIH's budget in the coming months. The NIH's annual budget is due to be released in the coming weeks, and analysts will be watching closely to see how it is received by lawmakers and investors alike. With the NIH playing a critical role in driving innovation and advancing medical research, any changes to its budget could have significant implications for the broader economy.